Primary prevention of cardiovascular disease

BMJ

Volumn 342, Issue 7792, 2011, Pages 291-

  Reckless, John P D ^a  

^a ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; EDITORIAL; HEALTH CARE FINANCING; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; SCREENING;

CARDIOVASCULAR DISEASES; GREAT BRITAIN; HEALTH PROMOTION; HUMANS; PRIMARY PREVENTION; STATE MEDICINE;

EID: 79551637807     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d201     Document Type: Editorial

References (12)

1. Hingorani AD, Hemingway H. How should we balance individual and population benefits of statins for preventing cardiovascular disease? BMJ 2011;342:c6244.
2. Khunti K, Walker N, Sattar N, Davies M. Unanswered questions over NHS health checks. BMJ 2010 2011;342:c6312.
3. Serumaga B, Ross-Degnan D, Avery AJ, Elliott RA, Majumdar SR, Zhang F, et al. Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom: interrupted time series study. BMJ 2010 2011;342:d108.
4. National Heart Lung and Blood Institute. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2004. www.nhlbi.nih.gov/guidelines/cholesterol/ index.htm.
5. Davis M, Durrington PN, Kirby M, Patel V, Potter J, Poulter N, et al; on behalf of the Joint British Societies (British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association). JBS-2: joint British societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(suppl V):v1-52.
6. National Institute for Health and Clinical Excellence. Lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. CG67. 2008. www.nice.org.uk/nicemedia/pdf/ CG67NICEguideline.pdf.
7. Marshall T. Targeted case finding for cardiovascular prevention: the obvious and sensible choice compared with universal screening. BMJ 2010;340:987-8.
8. National Institute for Health and Clinical Excellence. Identification and management of familial hypercholesterolaemia. CG71. 2008. www.nice.org.uk/ nicemedia/pdf/CG071NICEGuideline.pdf.
9. Department of Health. Putting prevention first - vascular checks: risk assessment and management. 2008. www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH-083822.
10. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
11. Kotseva K, Wood D, De Backer D, De Bacquer D, Pyorala K, Keil U; on behalf of the EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121-37.
12. Kotseva K, Wood D, De Backer D, De Bacquer D, Pyorala K, Reiner Z, Keil U; the EUROASPIRE Study Group. EUROASPIRE III: management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010;17:530-40.